Kyverna Therapeutics, Inc.
KYTX
$9.40
$0.040.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -0.84% | -6.65% | -46.10% | -67.22% | -81.40% |
| Total Depreciation and Amortization | -34.64% | -25.63% | -2.83% | 3.94% | 21.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,386.98% | 59.73% | 548.39% | -44.41% | -126.70% |
| Change in Net Operating Assets | 5,000.00% | -268.53% | 86.64% | -18.82% | -96.63% |
| Cash from Operations | 9.54% | -57.59% | -32.16% | -75.96% | -99.65% |
| Capital Expenditure | 100.19% | 98.04% | 99.61% | -- | -59.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -158.10% | 2,790.62% | 143.61% | 104.56% | -7.06% |
| Cash from Investing | -159.16% | 3,236.83% | 142.94% | 104.54% | -7.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 65.59% | 50.41% | -11.02% | -47.62% | -12.79% |
| Issuance of Common Stock | 363,153.13% | 1,734.44% | -100.00% | -100.00% | -88.36% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 17.24% | 97.43% | 100.00% |
| Cash from Financing | 65,561.86% | 1,078.95% | -14.06% | -100.12% | 85.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,216.58% | 28.51% | 96.30% | -120.96% | -168.93% |